Novartis Seeks Immediate Mandate After Drug Patent Invalidity Reversal
WASHINGTON, D.C. — A maker of generic drugs on Jan. 13 told the Federal Circuit U.S. Court of Appeals that it should deny Novartis Pharmaceuticals Corp.’s motion to expedite the issuance...To view the full article, register now.
Already a subscriber? Click here to view full article